Definition of tumor antigens suitable for vaccine construction

Seminars in Cancer Biology

Volumn 6, Issue 6, 1995, Pages 321-327

  Lewis, Jonathan J ^a   Houghton, Alan N ^b  

^a Department of Obstetrics Gynecology   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibodies; Immunotherapy; Molecular immunology; T lymphocytes; Tumor antigens; Vaccines

Indexed keywords

RECOMBINANT VACCINE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANIMAL; CHEMISTRY; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; VACCINES, SYNTHETIC;

EID: 0029421781     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/1044-579X(95)90001-2     Document Type: Article

References (47)

1. Wilson RE, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE (1968) Immunologic rejection of human cancer transplanted with a renal allograft. N Engl J Med 278:479-483
2. Snell GD, Stimpfling JH (1965) Genetics of Tissue Transplantation, in (Green EL, ed.) 2nd ed. pp 457-491. McGraw-Hill, New York
3. Foley EJ (1953) Antigenic properties of methvlcholanthrene- induced tumors in mice of the strain of origin. Cancer Res 13:835-837
4. Prehn RT, Main JM (1957) Immunity to methylcholanlhrene- induced sarcomas. J Natl Cancer Inst 18:769-778
5. Hewitt HB, Blake ER, Walder AS (1976) A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33:241-259
6. Hewitt HB (1978) The choice of animal tumors for experimental studies of cancer therapy. Adv Cancer Res 27:149-200
7. Boon T (1993) Teaching the immune system to fight cancer. Sci Am 266:82-89
8. Cote RJ, Morrissey DM, Houghton AN, Thomson TM, Daly ME, Oettgen HF, Old LJ (1986) Specificity analysis of human monoclonal antibodies reactive widi cell surface and intracellular antigens. Proc Nad Acad Sci USA 83:2959-2963
9. Houghton AN (1991) Cancer vaccines: Readdressing an old concept, in Immunomodulation in Cancer: Critical Issues for Therapeutic Design(Borden EC, ed.) pp 47-62. Mediscript, London
10. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373-1384
11. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T (1989) Structure of the gene of turn- transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293-303
12. Knuth A, Danowski B, Oettgen HF, Old L (1984) T-cell mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin-2-dependent T-cell cultures. Proc Natl Acad Sci USA 81:3511-3515
13. Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Ind J. Cancer 39:390-397
14. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
15. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie PG, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp Med 178:489495
16. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K, Boon T (1994) Two tyrosinase non- apeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J. Immunol 24:759-764
17. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari T, De Plaen E, Lurquin C, Szikora J-P, Renauld J-C, Boon T (1994) A new gene encoding for a differentiation antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp Med 180:35-41
18. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Apella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-22 restricted tumor infiltrating lymphocytes. J. Exp Med 180:347-352
19. Mattes JM, Thomson TM, dlk LJ, Lloyd KO (1983) A pigmentation-associated, differentiation antigen of human melanoma defined bv a precipitating antibody in human serum. Int J. Cancer 32:717-721
20. Wang R, Robbins PF, Kawakami Y, Kang X, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp Med 181:799-804
21. Cox AL., Skipper J., Chen Y., Henderson RA., Darrow TL., Shabanowitz J., Engelhard VH., Hunt DF., Craig L., Slingluff, J. (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
22. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehman- Hieb E, De Plaen E, Hankeln T, Beach D (1995) A pl6-insensi- tive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1285
23. Crawford LV, Pim DC, Billbrook RD (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30:403-408
24. Davidoff AM, Iglehart D, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Nad Acad Sci USA 89:3439-3442
25. Jung S, Schluesener H (1991) Human T lymphocytes recognize a peptide of single point-mutated oncogenic ras proteins. J Exp Med 173:273-276
26. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Lydon N, McGlynn E, Moe R, Cheever MA (1994) Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-22
27. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69:1051-1065
28. Young L, Alfieri C, Hennessy K, Evans H, O’Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, et al (1989) Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321:1080-1085
29. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337:320-322
30. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, Stein H (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Nad Acad Sci USA 88:4766-4770
31. Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Nad Acad Sci USA 80:3812-3815
32. McCance DJ, Walker PG, Dyson JL, Coleman DV, Singer A (1983) Presence of human papillomavirus DNA sequences in cervical intraepithelial neoplasia. Br Med J 287:784-788
33. Klein E (1968) Tumors of the skin. X. Immunotherapy of cutaneous and mucosal neoplasms. NY State J Med 68:900-911
34. Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC (1974) BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann Surg 180:635-643
35. Mastrangelo MJ, Berd D, Bellet RE (1976) Critical review of previously reported clinical trials of cancer immunotherapy with nonspecific immunostimulants. Ann NY Acad Sci 277:94-123
36. Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB (1978) Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dini- trochlorobenzene. Cancer 41:2456-2463
37. Pinsky CM, Camacho FJ, Kerr D, Geller NL, Klein FA, Herr HA, Whilmore WF, Jr, Oettgen HF (1985) Intravesical administration of bacillus Calmctte-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: Report of a prospective, randomized trial. Cancer Treat Rep 69:47-53
38. Herr HW, Laudone VP, Badalameiu RA, Oettgen HF, Sogani PC, Freedman BD, Melamed MR, Whitmore WF, Jr (1988) Bacillus Calmette-Guerin Lherapy alters the progression of superficial bladder cancer. J Clin Oncol 6:1450-1455
39. Livingston P (1991) Active specific immunotherapy in the treatment of patients with cancer. Immunol Allerg)’ Clin North Am 11:401-423
40. Hoover HC, Jr, Surdyke MG, Dangel RB, Peters LC, Hanna MG, Jr. (1985) Prospectively randomized trial of adjuvant active- specific immunotherapy for human colorectal cancer. Cancer 55:1236-1243
41. Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J, (1987) Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens [published erratum appears in Cancer 1988 Mar 15;6I (6): 1090]. Cancer 60:1249-1262
42. Livingston PO, Ritter G, Calves MJ (1989) Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol Immunother 29:179-184
43. Ritter G, Boosfeld E, Markstein E, Yu RK, Ren SL, Stallcup WB, Oettgen HF, Old LJ, Livingston PO (1990) Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. Cancer Res 50:1403-1410
44. Ravinclranath MH, Morton DL, line RF (1989) An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891-3897
45. Euhus DM, Gupta RK, Morton DL (1989) Induction of antibodies to a tumor-associated antigen by immunization widi a whole melanoma cell vaccine. Cancer Immun Immunother 29:247-254
46. Barnd DL, Un M, Metzgar RS, Finn OJ (1989) Specific, MHC- unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Nad Acad Sci USA 86:7159-7165
47. Livingston PO, Shiku M, Bean MA, Pinsky CM, Oettgen HF, Old LJ (1979) Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int J Cancer 24:34-44